Description

Transforming growth factor β (TGF-β) is a cytokine that has critical functions in the immune response by regulating Treg and Th17 cells. TGF-β is first synthesized as pro-TGF-β and then it is cleaved by furin proprotein convertase in the Golgi apparatus to produce the dimeric propeptides called latency-associate peptide (LAP) that non-covalently associates with the dimeric mature TGF-β to prevent its activity. This complex can further associate with latent-TGF-β-binding protein (LTBP) to produce a large latent form for deposition onto the extracellular matrix. The latent-TGF-β can be expressed on the membrane of activated Treg cells, immature dendritic cells, megakaryocytes, and platelets.

Formulation

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Oida T, et al. 2010. PLoS One 5:e15523. (FC, IP, WB)
2. Oida T, et al. 2011. PLoS One 6:e18365. (Neut)